AX-2026-043665 · GHRP-2 · BCH lot BCH-2508-M6766

Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 35 min gradient, 214 nm	98.73	% area	≥ 99.0	FAIL
Total impurities	RP-HPLC, sum of reported peaks	1.27	% area	≤ 1.0	FAIL
Largest single impurity	RP-HPLC — des-Lys (−128 Da)	0.47	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	817.4275	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	817.4285	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+1.2	ppm	± 15	PASS
Total peptide content	by difference from the gravimetric mass balance	88.67	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	87.54	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	5.13	mg	5 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	4.491	mg	5 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	89.8	%	90.0 – 110.0	FAIL
Water content	Karl Fischer, coulometric, duplicate	5.38	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	5.77	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.18	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear after 90 s gentle swirling, no particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.42	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 35 min gradient	10.27	min	10.45 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.02	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	78,295	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-2-Nal]-epimer	1.09	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 35 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 78,295, and skew follows the reported asymmetry factor of 1.02. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.47 % impurity against a 98.73 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	GHRP-2 — main peak	10.27	4,798,584	98.73	—
2	des-Lys (−128 Da)	9.99	22,843	0.47	-128.095
3	C-terminal free acid (+1 Da)	10.46	15,553	0.32	+0.984
4	[D-2-Nal]-epimer	10.11	12,637	0.26	0.000
5	oxidised Trp (+16 Da)	9.85	10,693	0.22	+15.995
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 817.4275 Da, computed from C45H55N9O6. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 817.4285 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
2+	409.7210	409.7215	0.0005	49.8
1+	818.4348	818.4358	0.0010	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	5.38
Counter-ion (acetate)	ion chromatography	5.77
Residual solvent + inorganic residue	estimated	0.18
Total peptide content	by difference	88.67
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.93	98.73	divergence +0.18 pp vs batch median
Total impurities (% area)	not stated	1.27
Largest single impurity (% area)	not stated	0.47
Water (%)	4.7	5.38
Counter-ion (%)	4.4	5.77
Peptide content (%w/w)	99.4	88.67
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (2–8 °C, 19 d) → laboratory (courier, ambient, 2 d) → assay.
Assay date: 10 Jan 2026
Submitted to the index: 03 Feb 2026
Laboratory: Nordanalyt Laboratories, Uppsala, Sweden
Method basis: 35 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 4

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

hilic_hana03 Feb 2026

Short and polar sequences are poorly served by reverse phase, and a low area-percent figure on one can be a method artefact rather than a material property. HILIC or ion pairing would settle it.

deamidation_rate03 Feb 2026

Deamidation adds one dalton, which at this mass is close to the resolution of the question rather than to the resolution of the instrument. The named-impurity table is the better place to look for it.

storage_stated03 Feb 2026

Stated storage conditions on the certificate against the observed transit conditions in the custody block: on this record they agree, which removes one class of explanation for anything unexpected.

quarter_over_quarter03 Feb 2026

A longitudinal set of retail purchases from one supplier across four quarters is the strongest supplier-level evidence available. Several contributors here are building exactly that.

Section 7

Related records

Same batch — lot BCH-2508-M6766 n=9

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043666	BCH-2508-M6766	Janoshik	2026-Q1	98.66	5.67	—	Supplier-supplied	1	FAIL
AX-2026-043667	BCH-2508-M6766	Medutest	2026-Q1	99.10	5.32	—	Supplier-supplied	1	MARGINAL
AX-2026-043668	BCH-2508-M6766	PeptideMeter	2026-Q1	98.75	5.35	104.1	Buyer-sourced	1	FAIL
AX-2026-043669	BCH-2508-M6766	Janoshik	2026-Q1	98.50	5.24	100.9	Buyer-sourced	1	FAIL
AX-2026-043670	BCH-2508-M6766	PeptideMeter	2026-Q1	99.10	5.47	106.8	Supplier-supplied	1	MARGINAL
AX-2026-043671	BCH-2508-M6766	PeptideMeter	2026-Q1	98.81	4.83	—	Buyer-sourced	1	FAIL
AX-2026-043672	BCH-2508-M6766	Janoshik	2026-Q1	98.61	6.24	96.4	Buyer-sourced	1	FAIL
AX-2026-043673	BCH-2508-M6766	PeptideMeter	2026-Q1	99.26	5.69	103.4	Buyer-sourced	1	MARGINAL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent GHRP-2 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-042471	HJ	HJ-2602-W4961	VendorInvestigate	2026-Q2	99.03	1.69	—	Buyer-sourced	PASS
AX-2026-042473	HJ	HJ-2602-W4961	Nordanalyt	2026-Q2	99.08	1.28	—	Buyer-sourced	PASS
AX-2026-042313	Homopeptide	HOMO-2602-E2105	Janoshik	2026-Q2	99.91	4.51	90.4	Buyer-sourced	PASS
AX-2026-042312	Homopeptide	HOMO-2602-E2105	Medutest	2026-Q2	99.44	4.16	—	Buyer-sourced	PASS
AX-2026-042316	Homopeptide	HOMO-2602-E2105	Janoshik	2026-Q2	99.90	4.39	103.7	Buyer-sourced	PASS
AX-2026-042468	HJ	HJ-2602-W4961	Janoshik	2026-Q2	99.21	1.22	102.3	Buyer-sourced	PASS
AX-2026-042472	HJ	HJ-2602-W4961	Medutest	2026-Q2	99.11	1.73	—	Buyer-sourced	PASS
AX-2026-042475	HJ	HJ-2602-W4961	Janoshik	2026-Q2	99.12	1.46	—	Buyer-sourced	PASS

Other recent BCH records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043691	BPC-157	BCH-2603-L7768	Janoshik	2026-Q3	98.66	5.12	—	Supplier-supplied	1	MARGINAL
AX-2026-043693	BPC-157	BCH-2603-L7768	PeptideMeter	2026-Q3	97.82	5.21	94.9	Buyer-sourced	0	FAIL
AX-2026-043686	BPC-157	BCH-2603-L7768	VendorInvestigate	2026-Q3	97.64	5.27	—	Buyer-sourced	0	FAIL
AX-2026-043695	BPC-157	BCH-2603-L7768	Janoshik	2026-Q3	97.61	5.42	—	Buyer-sourced	0	FAIL
AX-2026-043726	N-Acetyl Semax Amide	BCH-2602-E8475	Janoshik	2026-Q3	97.89	9.67	104.2	Buyer-sourced	0	FAIL
AX-2026-043688	BPC-157	BCH-2603-L7768	Janoshik	2026-Q3	97.94	5.56	—	Buyer-sourced	0	FAIL
AX-2026-043658	BPC-157	BCH-2603-G6644	Janoshik	2026-Q3	98.45	4.37	101.8	Supplier-supplied	0	PASS
AX-2026-043692	BPC-157	BCH-2603-L7768	VendorInvestigate	2026-Q3	97.60	5.61	—	Buyer-sourced	0	FAIL